Dozens of Top Scientists Sign Effort to Prevent A.I. Bioweapons

Dario Amodei, chief executive of the high-profile A.I. start-up Anthropic, told Congress last year that new A.I. technology could soon help unskilled but malevolent people create large-scale biological attacks, such as the release of viruses or toxic substances that cause widespread disease and death. Senators from both parties were alarmed, while A.I. researchers in industry…

Read More

Some Product Ideas to Consider

This column is part of a series for the Design special section of The New York Times. Readers are invited to send questions to designadvice@nytimes.com. After a column I wrote last summer that touched on Ping-Pong tables, a reader asked if I could recommend companies supplying a pinball machine for his home. In researching, I…

Read More

F.D.A. Delays Action on Closely Watched Alzheimer’s Drug

The Food and Drug Administration has decided to delay action on a closely watched Alzheimer’s drug, donanemab, which the agency was widely expected to approve this month. The F.D.A. will instead require donanemab to undergo the scrutiny of a panel of independent experts, the drug’s maker, Eli Lilly and Company, said Friday. “The F.D.A. has…

Read More

Good News and Bad News for Astronomers’ Biggest Dream

The United States should commit $1.6 billion to building an “extremely large telescope” that would vault American astronomy into a new era, according to the National Science Board, which advises the National Science Foundation. In a statement on Feb. 27, the board gave the foundation until May to decide how to choose between two competing…

Read More